Summary: Plasmid DNA is a critical raw material for cell and gene therapies. Discover the importance of having an integrated partner like Catalent Cell & Gene, and how we can keep your development and manufacturing on track and on schedule.
Summary: The Catalent team has broad expertise in developing customized plasmid DNA manufacturing solutions, from plasmid engineering to large-scale GMP plasmid production.
Summary: Learn how Catalent Cell & Gene Therapy recognizes the challenges faced when obtaining raw materials, and how our investments in pDNA manufacturing secure our integrated supply chain.
Summary: Learn how integrated service providers can streamline manufacturing, development and commercialization for optimal regulatory and process outcomes for gene therapy programs.
Summary: Along with the complexities of vaccine and viral-based gene therapy process development comes the need for analytical techniques that can help assess quality parameters, in real-time.
Summary: In this executive summary, our expert discusses how Catalent Cell & Gene Therapy continues to learn about formulating gene therapies by adapting methods used for other biologics.
Summary: In this on-demand webinar, our expert discusses how Catalent Cell and Gene Therapy is working towards an approach for gathering product knowledge and establishing formulation selection criteria using traditional/routine techniques as well as evaluating novel methodologies for gene therapy products.
Summary: Catalent offers tools to measure the ratio and help assess the safety and efficacy of viral vector-based therapies.
Summary: In this webinar, hear from Catalent panelists as they discuss navigating the path from research lab to the clinic.
Summary: Radiance® data is presented on rapid and low error adenovirus and baculovirus infectivity measurements as well as AAV transfection monitoring.
Summary: The successful outcomes delivered by cell and gene therapies coupled with emergence of modalities across nucleic acid therapeutics and microbiomes pose the next challenge for innovators to make these new modalities…
Summary: Catalent CEO John Chiminski to talks about the year ahead, offering projections for what 2021 holds in store for the biopharma industry.
Summary: Catalent Cell & Gene Therapy is a premier partner for innovators across the entire field of advanced biotherapeutics. Explore our development and manufacturing capabilities for allogeneic and autologous cell therapies, viral vector-based…
Summary: In this on-demand webinar from the 2020 CPhI Festival of Pharma, panelists discuss innovative technologies and their adoption for cell and gene therapies.
Summary: Julien Meissonnier, Catalent’s Vice President and Chief Scientific Officer, discusses innovative approaches, technology disrupters, and more in this webinar.
Summary: Learn about the complexities from raw material supply through drug product manufacturing, including planning early for a commercial-ready process.
Summary: This panel discussion highlights technical and regulatory hurdles associated with development and manufacturing steps, and strategies and solutions to facilitate development through commercialization.
Summary: Learn about specific case studies for neuromuscular degenerative indications, AAV technology and manufacturing, strategies for navigating the current regulatory environments.
Summary: Learn about Catalent’s journey into the Cell and Gene therapy space, overcoming challenges, and the company’s commitment to its partners.
Summary: What hurdles need to be overcome before gene therapy is the new modality in the cancer therapy arsenal? We’ll look at manufacturing, viral vectors, and the most promising approaches coming to the clinic.
Summary: Catalent and LumaCyte experts collaborate to compare AAV production with three different transfection reagents.
Summary: To minimize off-line manipulations with aseptically-closed bioreactor system, iCELLis® Nano tubing assemblies were designed to use on-line bio-welding technology for each step from…
Summary: kLa estimations were performed for the iCELLis® Nano and iCELLis® 500 bioreactors with equivalent packed-bed size and compaction (4m2 and 500m2).
Summary: Gene therapy is a rapidly growing area in healthcare but, now the promise has been shown, we must focus on improving the manufacturing process and reducing…
Summary: Gene therapies have been exploding in popularity and lining up new programs looking to create a new standard of care models for a wide variety of diseases.